MediGene AG · LS:A40ESG
MediGene — Q1 2012 Earnings Presentation
15 slides from MediGene's earnings presentation, May 11, 2012
Slide 1: Analyst Conference Call Financial Results 3 Months 2012
Analyst Conference Call Financial Results 3 Months 2012 May 11, 2012 Dr. Frank Mathias, CEO Arnd Christ, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Major achievements in first months of 2012
Major achievements in first months of 2012 Veregen®: Positive decision on marketing authorization for additional 17 European countries, as well as local market approvals in Sweden, Norway and Poland Market approval for Switzerland received EIP Eczacibasi new partner in Turkey Eligard® milestone paym
Slide 4: Clinical formulation study with RhuDex successfully completed
Clinical formulation study with RhuDex® successfully completed All dosing rounds were conducted successfully Data is currently being analyzed in detail; full data set is expected for mid 2012 Clear indication of favorable safety profile Preparations for production of GMP material ongoing 4
Slide 5: Positive preclinical data on AAVLP
Positive preclinical data on AAVLP In vivo HPV protection data was generated by researchers at Johns Hopkins University School of Medicine, USA Positive data show that vaccination of mice with an AAVLP vaccine carrying HPV L2 epitopes at two surface sites Induces cross-neutralizing antibodies active
Slide 6: Financial Report Q1 2012
medigene Financial Report Q1 2012
Slide 7: Key figures for the first quarter of 2012
Key figures for the first quarter of 2012 Total revenues of €1.6 million Veregen® product sales and royalties of €0.6 million Eligard® royalties of €0.6 million Other income of €0.4 million EBITDA result From continued operations: €-2.0 million (Q1 2011: €-2.9 million) Total: €-2.0 million (Q1 2011:
Slide 8: Increasing Veregen revenues
Increasing Veregen® revenues In € million Total Veregen® in market sales Total Veregen® revenue 36% 59% 0.6 0.4 Q1 2011 Q1 2012 Q1 2011 Q1 2012 Veregen® revenue Q1 2012 Q1 2011 Change Product sales 0.2 0.0 - Royalties 0.4 0.3 36% Milestones 0.0 0.1 - Total Veregen® revenue 0.6 0.4 59% 8
Slide 9: Operating expenses supporting corporate strategy
Operating expenses supporting corporate strategy In € million R&D expenses SG&A expenses -9% 7% 2.0 1.6 1.8 1.8 Q1 2011 Q1 2012 Q1 2011 Q1 2012 Lower personnel and facility Higher expenses associated expenses with Veregen® business Higher clinical development Higher BD expenses costs 9
Slide 10: EBITDA and net result within guidance
EBITDA and net result within guidance In € million EBITDA (continued operations) Net result (continued operations) -2.0 -2.3 -2.9 -3.1 Q1 2011 Q1 2012 Q1 2011 Q1 2012 Total EBITDA* Total net result* 19.2 17.0 -2.0 -2.3 Q1 2011 Q1 2012 Q1 2011 Q1 2012 * Includes €20 million milestone payment in Q1 20
Slide 11: Financing secured beyond 2013
Financing secured beyond 2013 In € million -2.5 -0.1 0 -0.1 12.8 10.1 Cash as of Cash flow from Cash flow from Cash flow from Foreign exchange Cash as of Jan. 1, 2012 operating activities investing activities financing activities differences Mar. 31, 2011 Average monthly operating cash burn of €0.
Slide 12: We confirm our financial guidance for 2012
We confirm our financial guidance for 2012 Guidance 2012 Revenue from continued operations greater than €5 million Revenue from discontinued operations €5 million loss in mid-single digit EBITDA million range 12
Slide 13: Product and project outlook
Product and project outlook Veregen® Approvals and market launches in addtional countries Additional marketing partnership agreements Revenue growth EndoTAG®-1 One or more development and marketing partnerships RhuDex® Final study report of formulation study Continuation of clinical development AAVL
Slide 14: Questions & Answers
Questions & Answers Dr. Frank Mathias, CEO Arnd Christ, CFO 14
Slide 15: Medigene AG contact details
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg/Martinsried Planegg / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG, Prime Standard)